Patent/Application number.
|
Title and Basis
|
Official inventor(s) -
|
|
Subject.
|
Applicant |
PCT Pub. No.: WO9811133
EU Patent: EP0941240
US Patent: 7.101.554
First filed:
11. Sep. 1996 (EU)
9. Sep. 1997 (USA)
|
"New Picornaviruses, vaccines and diagnostic kits."(EU).
"Picornaviruses, vaccines and diagnostic kits" (USA)
Patent based on this paper : Niklasson et al, 1999. |
Bo Niklasson
|
Patent granted in EU (EPOline *) and USA (USPTO**) |
The sequence of the Ljungan virus is protected, along with its uses in future
prophylactic
treatments (vaccines) against diabetes, heart disorders and a multitude of other disorders and illnesses.
Two other derived applications have recently been filed to USPTO (7. Jun. 2006 and 29. Jun. 2006)
|
The applicant in Europe was originally the Swedish company Microtus AB , then Nya Apodemus AB and now Apodemus AB.
In USA the applicant is always the inventor(s); in this case Niklasson. |
PCT Pub. No. WO03019197 (EU)
Document number:
20040265793 (USA)
First filed:
22. August 2001(EU).
12. August 2004 (USA) |
"Diabetic Model" (EU and USA)
Patent application based on these papers: Niklasson et al., 2003a and Freimanis et al., 2003. |
Bo Niklasson
Ake Lernmark
|
Pending in EU
Pending in USA
|
Seek to protect the use of diabetic bank voles as a new animal model for type 1 diabetes in addition to the use of a general method to facilitate the development of diabetes. The method consists in subjecting the animal model to "stress" (in this case a bank vole, but excisting animal models will probably fall under the claims too).
Apparently the application in addition covers the use of diabetic bank voles regardless of any previous infection with Ljungan virus. |
The applicant in Europe is the Swedish company Apodemus AB.
In USA the applicant is Niklasson and Lernmark |
PCT Pub. No. WO03091386 (EU)
Document number:
20050233311 (USA)
First filed:
23. April 2002 (EU)
15. June 2005 (USA)
|
"A new family of Picornaviruses"(EU)
"Family of picornaviruses" (USA)
Patent application was (is) based on this paper : Johansson et al., 2002.
|
Michael Lindberg
Susanne Johansson
Bo Niklasson |
Withdrawn in EU.
Pending in USA |
Sought (seek, in USA) to protect a part of the Ljungan virus genome.
|
Both in EU and in USA the applicants is the official inventors, Lindberg, Johansson and Niklasson. |
PCT Pub. No. WO2004073710 (EU)
Document number:
20060018876 (USA)
First filed:
21 February 2003 (EU)
22. August 2005 (USA)
|
"Treatment of diseases caused by Ljungan virus by using Pleconaril" (EU)
"Treatment of diseases caused by viral infection" (USA)
It appears for the moment as if this application is not based on a published scientific paper. |
Bo Niklasson
|
Grant of the patent is intended (Sep, 2007) (EU).
Pending in USA |
The use of the antiviral medicament PLECONARIL, or a derivate thereof, to treat a multitude of possible Ljungan virus induced illnesses. 14 claims in total (EU).
In the American application there is at present 19 claims where the first 14 in effect is similar to the European application. The last five claims specify that the preferred method to treat this Ljungan infection include treatment with antiserum (based on Ljungan virus antibodies) and Interferon, wherein said interferon includes .alpha..
|
The applicant in Europe is the Swedish company Apodemus AB.
In USA the applicant is Niklasson. |